{"data":{"id":373,"lang":"en","title":"Novo Nordisk Plunges 15% After Next-Gen Obesity Drug CagriSema Loses Head-to-Head Trial Against Eli Lilly's Zepbound","summary":"Novo Nordisk stock crashed 15% after CagriSema achieved only 20.2% weight loss vs 23.6% for Eli Lilly's Zepbound in the REDEFINE 4 trial.","category":"business","category_label":"Business","published_at":"2026-02-24T00:01:40Z","updated_at":"2026-02-24T00:01:40Z","url":"https://techtools.cz/tools/news/article/373-novo-nordisk-plunges-15-after-next-gen-obesity-drug-cagrisema-loses-head-to","api_url":"https://techtools.cz/news-api/v1/articles/373?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/373.md?lang=en","image_url":"https://www.statnews.com/wp-content/uploads/2025/12/GettyImages-2245790195.jpg","word_count":129,"reading_time_minutes":1,"sources":[{"url":"https://www.statnews.com/2026/02/23/novo-nordisk-cagrisema-fail-comparison-trial-zepbound-eli-lilly-obesity/","domain":"statnews.com"},{"url":"https://www.cnbc.com/2026/02/23/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html","domain":"cnbc.com"}],"translation":{"lang":"cs","id":363,"title":"Akcie Novo Nordisk spadly o 15 % poté, co lék na obezitu CagriSema prohrál přímé srovnání s Zepboundem od Eli Lilly","url":"https://techtools.cz/tools/news/clanek/363-akcie-novo-nordisk-spadly-o-15-pote-co-lek-na-obezitu-cagrisema-prohral-prime","api_url":"https://techtools.cz/news-api/v1/articles/363?lang=cs"},"content":"Novo Nordisk shares crashed over 15% on Monday after its next-generation weight loss drug CagriSema failed to match Eli Lilly's tirzepatide (sold as Zepbound) in the pivotal REDEFINE 4 trial. Over 84 weeks, CagriSema delivered 20.2% weight loss compared to 23.6% for tirzepatide — a 3.4-percentage-point gap that was statistically significant, meaning the drug failed its primary endpoint of non-inferiority.\n\nThe result is a major blow to Novo Nordisk, which had pinned its competitive strategy on CagriSema — a combination of semaglutide and cagrilintide — to reclaim ground in the booming obesity drug market. Eli Lilly shares rose 4% on the news, further cementing its dominance. Novo filed CagriSema for FDA approval late last year, with a decision expected by late 2026, but the failed trial raises questions about its commercial positioning."}}